Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
UOX
MCID: URT049
MIFTS: 25

Urate Oxidase, Pseudogene (UOX)

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Urate Oxidase, Pseudogene

About this section

MalaCards integrated aliases for Urate Oxidase, Pseudogene:

Name: Urate Oxidase, Pseudogene 56 13
Uricase 56
Uox 56

External Ids:

OMIM 56 191540
Sources

Summaries for Urate Oxidase, Pseudogene

About this section
OMIM : 56 In most mammals, the activity of urate oxidase (EC 1.7.3.3) catalyzes the oxidation of uric acid to allantoin; humans and some primates lack this enzyme activity. The loss of urate oxidase in the human during primate evolution predisposes man to hyperuricemia, a metabolic disturbance that can lead to gouty arthritis and renal stones (summary by Wu et al., 1994). (191540)

MalaCards based summary : Urate Oxidase, Pseudogene, also known as uricase, is related to gout and hyperuricemia. An important gene associated with Urate Oxidase, Pseudogene is UOX (Urate Oxidase (Pseudogene)). The drugs Febuxostat and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and endothelial.

Sources

Related Diseases for Urate Oxidase, Pseudogene

About this section

Diseases related to Urate Oxidase, Pseudogene via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 18)
# Related Disease Score Top Affiliating Genes
1 gout 10.9
2 hyperuricemia 10.9
3 diabetes insipidus, nephrogenic, autosomal 10.2
4 lymphoma, hodgkin, classic 10.2
5 lymphoma, non-hodgkin, familial 10.2
6 nephrolithiasis 10.2
7 diabetes insipidus 10.2
8 burkitt lymphoma 10.1
9 hepatocellular carcinoma 10.1
10 nephrolithiasis, calcium oxalate 10.1
11 wilms tumor 5 10.1
12 urolithiasis 10.1
13 glucose intolerance 10.1
14 hyperglycemia 10.1
15 uremia 10.1
16 severe combined immunodeficiency 10.1
17 fatty liver disease 10.1
18 rapidly involuting congenital hemangioma 10.1

Graphical network of the top 20 diseases related to Urate Oxidase, Pseudogene:



Diseases related to Urate Oxidase, Pseudogene
Sources

Symptoms & Phenotypes for Urate Oxidase, Pseudogene

About this section

Clinical features from OMIM:

191540
Sources

Drugs & Therapeutics for Urate Oxidase, Pseudogene

About this section

Drugs for Urate Oxidase, Pseudogene (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Febuxostat Approved Phase 4 144060-53-7 134018
2
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
3
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
6
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
7
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
8
Polyestradiol phosphate Approved Phase 4 28014-46-2
9
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
10
Uric acid Investigational Phase 4 69-93-2 1175
11 Tocotrienol Investigational Phase 4 6829-55-6
12 Antirheumatic Agents Phase 4
13 Pharmaceutical Solutions Phase 4
14 Protective Agents Phase 4
15 Angiotensinogen Phase 4
16 Giapreza Phase 4
17 Vitamins Phase 4
18 Insulin, Globin Zinc Phase 4
19 Lecithin Phase 4
20 Antihypertensive Agents Phase 4
21 insulin Phase 4
22 Silybin Phase 4
23 Tocopherols Phase 4
24 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
25 Tocotrienols Phase 4
26 Sodium Chloride Symporter Inhibitors Phase 4
27 Progestins Phase 4
28 Estradiol 17 beta-cypionate Phase 4
29 Angiotensin-Converting Enzyme Inhibitors Phase 4
30
protease inhibitors Phase 4
31 Estradiol 3-benzoate Phase 4
32 diuretics Phase 4
33 HIV Protease Inhibitors Phase 4
34 Estrogens Phase 4
35
Allopurinol Approved Phase 2 315-30-0 2094
36
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
37
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
38
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
39 Anti-Infective Agents Phase 2
40 Immunologic Factors Phase 2
41 Immunosuppressive Agents Phase 2
42 Anti-Bacterial Agents Phase 2
43 Antifungal Agents Phase 2
44 Antibiotics, Antitubercular Phase 2
45
Rasburicase Approved, Investigational Phase 1 134774-45-1
46 Antioxidants Phase 1

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed NCT01328769 Phase 4 Febuxostat;Placebo
2 Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study Completed NCT03538327 Phase 4 Silybin
3 Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. Completed NCT03921736 Phase 4 Perindopril;Hydrochlorothiazide;Estracomb TTS
4 Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout Completed NCT00325195 Phase 3
5 Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout Completed NCT01356498 Phase 3
6 A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout Completed NCT00111657 Phase 2
7 An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid Completed NCT02959918 Phase 2 SEL-212;SEL-037;SVP-rapamycin (SEL-110)
8 ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D Recruiting NCT03899883 Phase 2 Pegloticase 8 MG/ML [Krystexxa]
9 A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy Active, not recruiting NCT03905512 Phase 2 SEL-212;SEL-037;SEL-110;KRYSTEXXA®
10 A Cohort Dose-Escalation Phase 1 Study of Intramuscular Injection of Uricase-PEG 20 Unknown status NCT01038947 Phase 1
11 A Cohort Dose-Escalation Phase 1 Study of Intravenous Infusion of Uricase-PEG 20 Unknown status NCT01021241 Phase 1
12 A Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSS11 Administered Intravenously in Healthy Volunteers. Unknown status NCT03388515 Phase 1
13 An Open-Label, Sequential, Ascending Single-Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of an Intravenous Infusion of SEL-037 in Subjects With Elevated Blood Uric Acid Levels Completed NCT02464605 Phase 1
14 A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid Completed NCT02648269 Phase 1 SEL-110
15 The Relationship Between Uric Acid and Inflammatory Markers Completed NCT01323335 Phase 1 IV Uric Acid;IV Rasburicase
16 An Open Label, Single-dose, Dose-increasing Study to Assess the Safety, Tolerability, PK and Preliminary PD of PEGylated Recombinant Candida Urate Oxidase (SSS11) for Injection in Chinese Healthy Adult Volunteers Not yet recruiting NCT04047394 Phase 1 PEGylated recombinant candida urate oxidase
17 Association of Maternal Uric Acid With Maternal Condition and Fetal Outcome in Pregnant Women With Hypertension Unknown status NCT01523327
18 Differential Effects of Uric Acid and Xanthine Oxidoreductase on Endothelial Function and Oxydative Stress Completed NCT03395977 Placebos;Febuxostat;Rasburicase
19 Paediatric Obesity and Cardiovascular Dysfunction: Searching for Early Markers of Damage Active, not recruiting NCT03169257

Search NIH Clinical Center for Urate Oxidase, Pseudogene

Sources

Genetic Tests for Urate Oxidase, Pseudogene

About this section
Sources

Anatomical Context for Urate Oxidase, Pseudogene

About this section

MalaCards organs/tissues related to Urate Oxidase, Pseudogene:

40
Liver, Kidney, Endothelial, Testes, Heart, Brain, Retina
Sources

Publications for Urate Oxidase, Pseudogene

About this section

Articles related to Urate Oxidase, Pseudogene:

(show top 50) (show all 1050)
# Title Authors PMID Year
1
Evolutionary history and metabolic insights of ancient mammalian uricases. 56 61
24550457 2014
2
Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. 61 56
8290593 1994
3
Structural analysis of the gene encoding rat uricase. 61 56
1783398 1991
4
Urate oxidase: primary structure and evolutionary implications. 61 56
2594778 1989
5
A human genomic sequence highly homologous to the 3'-untranslated region of rat uricase mRNA. 56 61
3178807 1988
6
Localization of the human urate oxidase gene (UOX) to 1p22. 56
1395718 1992
7
Human urate oxidase gene: cloning and partial sequence analysis reveal a stop codon within the fifth exon. 56
2403354 1990
8
Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase. 56
3344434 1988
9
HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. 56
3821905 1987
10
A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. 56
3029599 1987
11
Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 56
13937884 1962
12
Species and sex differences in the blood clearance and immunogenicity of PEGylated uricase: A comparative 26-week toxicity study in rats and monkeys. 61
31610209 2020
13
The role of uric acid in inflammasome-mediated kidney injury. 61
32452918 2020
14
Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia. 61
32518351 2020
15
Hyperuricemia Predisposes to the Onset of Diabetes via Promoting Pancreatic β-Cell Death in Uricase-Deficient Male Mice. 61
32312870 2020
16
Construction and expression of recombinant uricase‑expressing genetically engineered bacteria and its application in rat model of hyperuricemia. 61
32323736 2020
17
Perfecting a high hypoxanthine phosphoribosyltransferase activity-uricase KO mice to test the effects of purine- and non-purine-type xanthine dehydrogenase (XDH) inhibitors. 61
31971609 2020
18
The consequences of altered microbiota in immune-related chronic kidney disease. 61
32437554 2020
19
J-shaped relationship between serum uric acid levels and the risk of ischemic stroke in high-risk individuals: A hospital-based observational study. 61
32447150 2020
20
Multimodal Enzyme Delivery and Therapy Enabled by Cell Membrane-Coated Metal-Organic Framework Nanoparticles. 61
32352801 2020
21
De novo design of functional zwitterionic biomimetic material for immunomodulation. 61
32523997 2020
22
Associations of serum iron and ferritin with hyperuricemia and serum uric acid. 61
32458239 2020
23
High-Dose IV Administration of Rasburicase Suppresses Anti-rasburicase Antibodies, Depletes Rasburicase-Specific Lymphocytes, and Upregulates Treg Cells. 61
32462555 2020
24
Development of Uric Acid Biosensor Using Gold Nanoparticles and Graphene Oxide Functionalized Micro-Ball Fiber Sensor Probe. 61
31831430 2020
25
Structure-Based Immunogenicity Prediction of Uricase from Fungal (Aspergillus flavus), Bacterial (Bacillus subtillis) and Mammalian Sources Using Immunoinformatic Approach. 61
32221804 2020
26
A ''naked-eye'' colorimetric and ratiometric fluorescence probe for uric acid based on Ti3C2 MXene quantum dots. 61
32081178 2020
27
Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation. 61
31996020 2020
28
Pharmacokinetics of Polyethylene Glycol-Modified Canine Uricase Following Single and Multiple Intravenous Injections in Cynomolgus Monkeys. 61
32162270 2020
29
A natural complex product Yaocha reduces uric acid level in a live zebrafish model. 61
32087362 2020
30
Potential of a sensitive uric acid biosensor fabricated using hydroxyapatite nanowire/reduced graphene oxide/gold nanoparticle. 61
31729094 2020
31
Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts. 61
31621967 2020
32
Electrochemical determination of uric acid in urine and serum with uricase/carbon nanotube /carboxymethylcellulose electrode. 61
31836385 2020
33
Uricase-deficient rat is generated with CRISPR/Cas9 technique. 61
32368418 2020
34
Metabolic Acidosis Alters Expression of Slc22 Transporters in Mouse Kidney. 61
32062662 2020
35
Arterial hypertension associated with hyperuricemia: features of heart damage. 61
32386373 2020
36
Hypouricemia: what the practicing rheumatologist should know about this condition. 61
31650389 2020
37
Brushing the surface: cascade reactions between immobilized nanoreactors. 61
31859312 2020
38
Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies. 61
32508839 2020
39
Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices. 61
31673974 2019
40
Severe Hypouricemia Impairs Endothelium-Dependent Vasodilatation and Reduces Blood Pressure in Healthy Young Men: A Randomized, Placebo-Controlled, and Crossover Study. 61
31752638 2019
41
Enhanced Performance of Reagent-Less Carbon Nanodots Based Enzyme Electrochemical Biosensors. 61
31861148 2019
42
A ratiometric fluorescent probe for detection of uric acid based on the gold nanoclusters-quantum dots nanohybrid. 61
31176998 2019
43
A dual-signal colorimetric and ratiometric fluorescent nanoprobe for enzymatic determination of uric acid by using silicon nanoparticles. 61
31705210 2019
44
Uricase-containing coacervate microdroplets as enzyme active membrane-free protocells for detoxification of uric acid in serum. 61
31675031 2019
45
Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy. 61
31253939 2019
46
The value of serum uric acid levels to differentiate causes of transient loss of consciousness. 61
31476728 2019
47
Application of cyclic voltammetry to analyse uric acid and reducing agents in commercial milks. 61
31151606 2019
48
Screening of single or combined administration of 9 probiotics to reduce ammonia emissions from laying hens. 61
30982063 2019
49
Fabrication of an efficient and sensitive colorimetric biosensor based on Uricase/ Th-MOF for uric acid sensing in biological samples. 61
31220726 2019
50
Mathematical modeling for bioprocess optimization of a protein drug, uricase, production by Aspergillus welwitschiae strain 1-4. 61
31506445 2019
Sources

Variations for Urate Oxidase, Pseudogene

About this section
Sources

Expression for Urate Oxidase, Pseudogene

About this section
Search GEO for disease gene expression data for Urate Oxidase, Pseudogene.
Sources

Pathways for Urate Oxidase, Pseudogene

About this section
Sources

GO Terms for Urate Oxidase, Pseudogene

About this section
Sources

Sources for Urate Oxidase, Pseudogene

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....